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The malignant capacity of skin tumours induced by expression of
a mutant H-ras transgene depends on the cell type targeted
Ken Brown, Douglas Strathdee*, Sheila Bryson, Wendy Lambie 
and Allan Balmain†
Background: Pinpointing the cells from which tumours arise is a major challenge
in tumour biology. Previous work has shown that the targeted expression of a
mutant ras gene within the interfollicular cell compartment of mouse skin induces
the formation of benign papillomas, but these do not spontaneously progress to
malignancy. We have investigated the carcinogenic effects of expressing the
same oncogene in a different population of epidermal cells.
Results: Expression of mutant ras from a truncated keratin 5 gene promoter,
which directs expression to the follicular and interfollicular cells of newborn mice
and the hair follicle cells of adults, stimulated the development of acanthotic areas
in newborn mice. Within one week of birth, the acanthotic skin developed areas of
carcinoma in situ and adult mice developed papillomas and keratoacanthomas,
the latter having a high frequency of spontaneous malignant transformation to
squamous and occasionally spindle carcinomas. The benign tumours that arose
had several hallmarks of tumours at a high risk of malignant progression, including
suprabasal cell proliferation and heterogeneous expression of keratin 13. In
contrast to tumours induced by expressing mutant ras under the control of the
keratin 10 or keratin 1 gene promoters, the formation of these lesions was not
dependent on wounding or a tumour promoter.
Conclusions: Benign tumours that are at a risk of malignant conversion are
primarily derived from cells located within the hair follicle, and the nature of the cell
in which tumour initiation occurs is a major determinant of malignant potential.
Background
Understanding the nature and location of the ‘target cell’
for carcinogenesis — the cell in a tissue from which a
tumour is most likely to arise — is a central problem of
tumour biology which has yet to be fully resolved. It is
generally assumed that the major target must be one of a
relatively small population of stem cells which reside,
usually within a protected niche, in mammalian tissues
[1]. Recent studies on the biology of immortalisation have
shown, however, that more differentiated cells, from
renewing epithelia such as skin, are capable of acquiring
an infinite life span, at least in cell culture [2]. This raises
the possibility that many cells that have left the stem cell
compartment and are further along the lineage to the com-
pletely differentiated state may, through acquisition of
sufficient genetic alterations, become capable of giving
rise to malignant tumours. It is also possible that there
may be a continuum of target cells in tissues in which the
stage of differentiation determines the malignant capacity,
as is seen in cells of the haematopoietic lineage [3]. Nev-
ertheless, most human tumours arise in self-renewing
epithelial tissues, and our knowledge of the relationships
between stem cells, target cells, and the malignant capac-
ity of tumours is extremely sparse.
We have previously attempted to address some of these
questions using two-stage chemical carcinogenesis in
mouse skin — in which papillomas are triggered by the
topical application of a tumour initiator followed by a
tumour promoter [4]. Several investigations have shown
that tumour initiation is irreversible and that the initiated
cell can persist within the epidermis for months to years
after the initial carcinogenic insult [5]. This agrees with
the generally accepted notion that tumour initiation must
alter a cell belonging to a long-lived population within a
stem cell compartment. Two separate populations of ker-
atinocytes are implicated in the renewal of the epidermis.
A number of studies have located putative stem cells in
the basal layer of the interfollicular epidermis [6–8],
though others have suggested the bulge region of the hair
follicle as the location of the stem cell compartment [9,10].
Significantly, much of the available data implicate the hair
follicle as playing a central role in skin tumorigenesis [11].
The malignant conversion of papillomas to carcinomas is
a relatively rare event in two-stage carcinogenesis, occur-
ring at a frequency of around 5–10%. Furthermore,
subsets of papillomas have either a reduced or an
increased [12–14] risk of progression, and these can be
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distinguished by changes in the expression of phenotypic
markers such as TGF-β [15,16], α6β4 integrin [17] and
keratin 13 [18]. The relationship between these low-risk
and high-risk papillomas is presently unclear. Some dif-
ferences in progression frequencies might arise as a con-
sequence of different initiating events within cells of the
same target population [15]. It seems extremely unlikely
that this is the explanation for the different progression
frequencies of papillomas initiated with dimethylbenzan-
thracene (DMBA) as the vast majority of tumours that
arise after treatment with this carcinogen have the same
initiating mutation at codon 61 of the Harvey ras (H-ras)
gene [19]. 
In order to address these potentially related questions of
target cell location and malignant conversion, we have
examined the consequences of expressing mutant H-ras
in different cellular compartments of the epidermis. Pre-
viously, transgenic mice were generated in which expres-
sion of a mutant H-ras gene was targeted to the
interfollicular compartment of the epidermis by using a
cytokeratin 10 promoter [20]. This promoter directs
expression mainly to suprabasal cells of the epidermis,
but also to a small population of basal cells [21]. The phe-
notype of the animals expressing the transgene (K10ras)
was, primarily, increased differentiation of the epidermis,
but they also developed benign papillomas at sites of pro-
motional stimuli such as scratching, wounding or treat-
ment with 12-O-tetradecanoylphorbol-13-acetate (TPA).
This result indicated that interfollicular cells can give rise
at least to benign tumours. Similar observations were
reported by Greenhalgh et al. [22] for animals (HK1.ras
mice) in which ras expression was driven by a modified
promoter from a human keratin 1 gene, which has a
slightly more widespread expression in basal cells but is
still restricted to the interfollicular epidermis. A common
feature, however, in all of these studies was the absence
of spontaneous malignant conversion in the benign
tumours which arose.
We describe here the results of expressing a mutant
H-ras transgene from a truncated keratin 5 promoter
element. In adult mice, this promoter induced transgene
expression almost exclusively in the hair follicle, where
one of the putative epidermal stem cell compartments is
located. A total of four transgenic mouse lines were
obtained, each of which developed spontaneous papil-
loma-like or keratoacanthoma-like skin tumours. The
latter type frequently underwent spontaneous conversion
to squamous carcinomas and occasionally to undifferenti-
ated spindle cell carcinomas. Targeted expression of
mutant ras in the hair follicle region of mouse skin can
therefore reproduce the complete spectrum of events in
multistage skin carcinogenesis.
Results
Hair follicle expression of lacZ driven by a truncated
keratin 5 promoter
A 1.3 kb fragment (K5) of promoter sequence from the
bovine cytokeratin III gene [23] (equivalent to human
keratin 5) was used to target transgene expression to the
basal layer of the epidermis. Cytokeratin 5 is normally
found in the basal layers of stratified epithelia and in the
outer root sheath cells of the hair follicle [24]. In order to
analyse the expression pattern driven by the K5 promoter
sequence, two lines of transgenic mice were produced
(K5lacZ mice) which contained a reporter construct con-
sisting of the gene encoding β-galactosidase under the
control of the K5 sequence. In newborn mouse skin, the
extent of transgene expression, as detected by β-galactosi-
dase staining, was highly variable. The occasional areas of
expression that were detected were highly mosaic and
staining was restricted to cells within the outer root sheath
of the hair follicle and to patches of interfollicular basal
cells (Figure 1a). Analysis of adult skin samples demon-
strated that fewer hair follicles showed positive β-galac-
tosidase staining, and staining in the interfollicular
epidermis was almost undetectable (Figure 1b). The
restricted expression pattern conferred by the shortened
promoter, which differs from the pattern described previ-
ously [25], might have been advantageous for our studies,
as in previous experiments we were unable to obtain
viable transgenic animals expressing a potent oncogene
such as H-ras from a full length (5.3 kb) promoter [20].
Research Paper  The malignant capacity of H-ras-induced skin tumours Brown et al.    517
Figure 1
LacZ expression in the skin of K5lacZ mice.
Sections of dorsal skin from (a) neonate and
(b) adult K5lacZ animals, stained for
β-galactosidase activity and counterstained
with eosin. LacZ expression can be seen in
the outer root sheath cells of the hair follicle
and in the interfollicular basal epidermis in
neonates; in the adult epidermis, however, the
expression is restricted to the hair follicle.
Skin abnormalities in neonatal K5ras transgenic mice
The 1.3 kb K5 promoter fragment was subsequently used
to drive the expression of a cDNA fragment encoding con-
stitutively activated H-Ras. From 30 founder transgenic
(K5ras) animals that contained this transgene, 15 had an
abnormal skin phenotype at birth. This typically pre-
sented as weal-like regions of raised and thickened skin
(Figure 2a), which developed within several days into
grossly thickened and hypopigmented papillomatous
masses (Figure 2b). Histological examination of the skins
showed hyperplastic acanthotic downgrowths
(Figure 3c,d). Normal hair follicles and associated
melanocytes were absent from the acanthotic areas,
although remnants of follicle structures were occasionally
found (Figure 3c). Non-acanthotic skin from these
newborn animals was usually hyperplastic, with appar-
ently normal hair follicles. In several sections, thickening
of the skin was due to regions of papillomatous hyperpla-
sia (Figure 3b) or sessile papillomas, which similarly
lacked normal hair follicles, but which contained remnants
of follicle structures. These findings are consistent with
abnormal proliferation and differentiation of the hair folli-
cle being involved in the development of both the acan-
thosis and papillomatosis.
Within several days, the acanthotic lesions usually became
3–10 mm thick and highly disorganised in structure, with
the surface becoming macroscopically papillomatous
(Figure 2b). Histological sections showed the rapid devel-
opment of dysplasia, with areas typical of carcinoma in situ
and invasive carcinoma (Figure 3e,f) becoming progres-
sively apparent between 7 and 10 days after birth, at
which age the animals died or had to be sacrificed. This
differs from the results found with HK1.ras mice [22] for
which the initial hyperplasia converted to massive hyperk-
eratosis within several weeks.
Spontaneous tumour progression in adult transgenic mice
Five K5ras founder animals that appeared normal at birth
gradually developed phenotypic abnormalities in adult-
hood, including papillomatous hyperplasia, vibrissae follicle
hyperplasia (Figure 2c), and overt tumour formation. Seven
founders gave rise to lines in which a proportion of trans-
gene-positive offspring were born with acanthotic lesions or
developed spontaneous skin tumours at anywhere from
between one week and one year of age. Four transgenic
lines chosen for further study, KT932, KT754, KT760, and
KT769, showed variable transgene copy number
(1–15 copies per cell) but very similar phenotypes. Only a
fraction of the mice that contained the transgene devel-
oped skin tumours, and from an initial study which exam-
ined 464 animals over 65 weeks, 141 (30%) developed skin
tumours. The tumour number in individual mice varied
from a solitary tumour to cases of animals with more than
ten tumours. Though occasional skin lesions were histolog-
ically characterised as papillomas, the tumours more com-
monly exhibited prominent acanthotic characteristics and
closely resembled keratoacanthomas (Figure 4a). Occasion-
ally, keratoacanthomas were observed in association with
abnormal or metaplastic hair follicles. Additionally, cystic
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Figure 2
Phenotype of K5ras mice. (a) Normal (left)
and transgenic (right) littermates 2 days after
birth. Note the abnormal skin wrinkling and
thickening in the transgenic pup. (b) Examples
of 6 day old pups with extensive (top) and
localised (centre) areas of abnormal
epidermis, compared to a normal littermate
(bottom). The gross thickening and lack of
hair in the affected regions is clearly apparent.
(c) The muzzle area of an adult transgenic
animal in which a small papilloma-type lesion
is associated with each vibrissa follicle.
(d) Three keratoacanthomas in various stages
of exfoliation in the dorsal skin of an adult
transgenic animal.
epithelial lesions lined by squamous epithelium, classified
as type 3 keratoacanthomas [26] (Figure 2d), were
obtained. None of the spontaneous tumours that arose in
the mice showed any signs of regression. Examination of
histological sections from keratoacanthomas often showed
areas of local invasion (Figure 4b), and about half of the
lesions progressed to squamous (Figure 4c) or spindle cell
(Figure 4d) carcinomas within a few months. In contrast,
true pendunculated papillomas which arose at lower fre-
quency in the K5ras mice showed no evidence of malig-
nant progression. The notion that many of the spontaneous
tumours had a high probability of malignant progression
was supported by labelling tumour sections with bromod-
eoxyuridine (BrdU) or staining them for keratin 13. Anti-
BrdU antibody staining of BrdU-labelled acanthotic lesions
and keratoacanthomas showed that they had a high BrdU-
labelling index and frequently showed labelled cells in the
suprabasal layers of the lesions (data not shown). These
features are characteristic of the high-risk tumours that
arise during two-stage chemical carcinogenesis in mouse
skin [15]. Similarly, results from the staining of frozen
tumour sections with an antibody directed against keratin
13 showed that many of the acanthotic lesions and keratoa-
canthomas contained regions of heterogeneous expression
of keratin 13, similar to that observed in high-risk papillo-
mas or carcinomas (data not shown) [18,27].
Transgene expression in tumours and adjacent hair
follicles
The presence of mutant human Ras protein in the affected
tissues of K5ras transgenic mice was confirmed by western
blotting. Protein extracts from tumours and normal skin
were immunoprecipitated with an anti-H-Ras antibody and
visualised using a pan-Ras antibody (Figure 5a). Mutant
H-Ras protein was seen in tumours, but was undetectable in
normal tissue. In order to characterise more fully the expres-
sion pattern of the transgene in the tumours, in situ hybridis-
ation, using a probe specific for the SV40 intron and
polyadenylation sequences of the transgene construct, was
carried out on sections from normal skin and tumours from
transgenic mice. No hybridisation signal was detected in fol-
licles or interfollicular epidermis in unaffected skin
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Figure 3
Histopathology of neoplasms in newborn
mice. (a) Normal skin and (b–f) lesions,
stained with haematoxylin and eosin, from
K5ras mice. (a) Normal dorsal skin from a
newborn mouse. (b) Papillomatous
hyperplasia from a 6 day old transgenic
animal. Note the absence of normal hair
follicles, though some hyperplastic follicular
structures can be seen on the right hand side
of the section (arrow). (c) Region of
acanthotic dorsal skin from a 6 day old animal,
with the vestigial remnant of a hair follicle bulb
(arrow). (d) Area from the margin of a lesion
showing the transition from hyperplastic
follicles containing intact hair shafts (left), to
squamous epithelial structures which contain
only occasional remnants of normal follicles
(centre and right). (e) Section of an acanthotic
lesion from a 7 day old mouse which exhibits
a more disorganised and dysplastic
epithelium, but which has not yet progressed
to invasive carcinoma. (f) Acanthotic lesion
taken from a 6 day old animal with an area of
invasive squamous carcinoma (bottom
centre).
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(Figure 5b). A detectable signal was observed, however, in
tumours and in follicles closely adjacent to tumours
(Figure 5c). This finding was consistent in acanthotic
lesions, papillomas, keratoacanthomas and carcinomas. The
expression pattern was not uniform in all basal cells
throughout the tumour, but was mosaic, with some areas of
the tumour expressing very high transgene levels. The
hyperplastic epidermis at the margins of the tumour was fre-
quently negative for detectable H-ras transgene expression.
Tumour development is not dependent on wounding or a
promotional stimulus
One prevalent feature of previously described transgenic
lines expressing ras constructs in the epidermis under the
control of the keratin 10 [20] or keratin 1 [22] promoter was
that papillomas tended to develop at sites of wounding or
scratching and, in particular, in response to treatment with
a tumour promoter. In contrast, spontaneous skin tumours
arising in the K5ras mice were neither more prevalent in,
nor restricted to, areas of grooming, scratching or wound-
ing, such as at the edges of ear-tag or tail-biopsy sites. A
group of 94 transgene-positive mice, some with pre-exist-
ing spontaneous tumours, were treated twice weekly with
TPA for 14 weeks to examine the effect of tumour promo-
tion. The results are summarised in Table 1. Though the
hyperplastic response to TPA treatment was normal, the
great majority of these animals appeared refractory to any
promotional stimulus, and TPA treatment did not result in
an increase in tumour incidence over that found in
untreated control animals. In contrast, five mice, two with
pre-existing papillomas, developed extensive papillomato-
sis after only two applications of TPA, similar to the reac-
tion reported for HK1.ras mice [28]. Unlike the reaction in
the HK1.ras mice, however, the papillomatosis in K5ras
mice did not regress and persisted for four weeks after
treatment, at which stage the mice were sacrificed.
Discussion
Consequences of mutant ras expression in different
epidermal target cells
The mouse H-ras gene can initiate skin tumours when
mutated by specific chemical carcinogens [13,19] or intro-
duced into epidermal cells by retroviral application in vivo
[29] or in vitro [30]. The critical target cell which suffers the
mutation and gives rise to the tumours has not been identi-
fied. Several groups have now attempted to reproduce the
features of chemical tumour initiation by expressing a
mutated H-ras gene in the epidermis of transgenic mice
using different keratin promoters. Initial studies, which
used either the keratin 10 or the keratin 1 promoter to target
ras expression to the interfollicular epidermis, demonstrated
that this cell population can give rise to papillomas at sites
exposed to wounding or tumour promoters [20,22]; malig-
nant progression of these tumours occurs very infrequently,
however, and only after a long latency period [28].
A substantially different phenotype is seen in animals
expressing the same mutant ras gene in hair follicles
under the control of a truncated keratin 5 promoter. In
adult mice, in which K5-directed expression is seen only
in the hair follicle, with virtually undetectable levels in
the interfollicular epidermis, there was no evidence of
hyperkeratosis, as reported for K10ras transgenic mice.
Spontaneous keratoacanthomas frequently developed,
consistent with a follicular origin. Importantly, many of
these tumours progressed to squamous carcinomas and/or
Figure 4
Histopathology of spontaneous neoplasms in
adult mice. Sections of skin tumours from
adult K5ras mice were stained with
haematoxylin and eosin. (a) A spontaneous
tumour from an adult animal, illustrating the
typical keratoacanthoma-like nature of the
lesions. (b) A higher magnification view of a
region from the base of the keratoacanthoma
shown in (a). Note the epithelial cell nests in
the dermal stroma and the lack of a clear
tumour–stroma interface, typical of a
carcinoma. (c) Section of a squamous
carcinoma. (d) Area of undifferentiated
spindle carcinoma.
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spindle cell carcinomas, thereby reconstituting all the
stages of tumour induction in mouse skin.
It could be argued that the dramatic contrast between the
consequences of expressing the same Ras protein using
the keratin 10 promoter and the K5 sequence is due to
quantitative differences in the levels of expression driven
by the two promoters in the same target cell population.
Quantitative alterations in the level of signalling through
the Ras pathway can influence the decision between pro-
liferation and differentiation in mouse PC12 cells [31], or
determine cell fate during development [32]. We think
that this is extremely unlikely to be the explanation of the
observed results, however. The levels of ras transgene
expression in unaffected skin are extremely low in both
K10ras and K5ras mice, as assessed both by in situ hybridi-
sation and by western blotting, suggesting that major dif-
ferences in the Ras protein levels cannot account for the
phenotypes seen. In contrast, the use of both in situ
hybridisation and reporter gene constructs have clearly
demonstrated the cell specificity in the expression pat-
terns driven by the K10 promoter and the K5 sequence.
Although expression levels of the human ras transgene
were too low to be detected in morphologically normal
skins of the K5ras mice, in situ hybridisation clearly
showed specific transgene expression in hair follicles adja-
cent to areas of dysplasia, but not in hyperproliferative
interfollicular epidermis. These data, together with the
patterns of hair follicle expression seen in K5lacZ mice and
in transgenic mice expressing the viral E1A protein under
the control of the keratin 5 promoter [33], argue strongly
that the contrasting phenotypes seen in the different ras-
expressing transgenic animals are due to differential tar-
geting of epidermal cell populations by the respective
keratin promoters, rather than to quantitative differences
in the levels of transgene expression in these mice.
The role of tumour promoters
An important feature that distinguishes the K5ras trans-
genic animals from others previously reported is the
absence of a strong effect of treatment with a tumour pro-
moter on tumour yield. Both the K10ras [20] and the
HK1.ras [22] mice developed papillomas at sites of wound-
ing or irritation, such as the tail, footpad or adjacent to ear
tags. The HK1.ras mice were extremely sensitive to treat-
ment with TPA, forming very large papillomatous lesions,
which regressed if treatment was interrupted. In a study of
Table 1
The effect of TPA treatment upon tumour formation in K5ras mice.
Before TPA treatment After TPA treatment
Number of mice Number of tumours Number of tumours Mice with new tumours
TPA-treated group With tumours 39 63 63 0*
Without tumours 55 7 7†
Untreated group With tumours 31 50 51 1
Without tumours 43 4 4
*Three mice in this group with papillomas developed acute papillomatosis in response to TPA treatment. †Two mice in this group developed acute
papillomatosis in response to TPA treatment.
Figure 5
H-ras transgene expression and localisation in tumours of K5ras mice.
(a) Western blot of immunoprecipitated H-Ras protein from four
spontaneous lesions arising in K5ras mice: lane 1, human mutant
H-Ras from cell line 1d1a; lane 2, acanthotic lesion; lane 3,
keratoacanthoma; lane 4, squamous carcinoma; lane 5, papilloma.
The upper band corresponds to the mutant human H-Ras protein,
which contains an amino acid substitution at Val12, and the lower
band is the endogenous mouse H-Ras protein, which has a faster
mobility. Only the lower band is detected in extracts from normal
mouse cells (data not shown). (b,c) Bright-field images showing in
situ hybridisation of transgene message to 35S-labelled SV40
antisense riboprobe. (b) In a section from unaffected dorsal skin of a
transgenic animal, H-ras transgene mRNA is not detectable. (c) A
section from the edge of a keratoacanthoma. Note that H-ras mRNA
is expressed in a follicle adjacent to the lesion (centre), and in some
areas of the tumour (right), but is absent from hyperplastic skin at the






2 3 4 5
(c)
more than 90 K5ras animals, however, only 5 showed a
strong papilloma response to TPA similar to that reported
for several lines of HK1.ras mice. The remainder of the
animals, although their skins showed the usual hyperplas-
tic response as a consequence of chronic TPA treatment,
did not develop more tumours than untreated transgenic
mice. These results suggest that the target cell population
that gives rise to carcinomas is not strongly stimulated by
tumour promoters, a result compatible with observations
that the incidence of chemically induced carcinomas is not
increased [34] by more extensive promoter treatment. 
The hair follicle in carcinogenesis
An association between hair follicle expression of ras and
skin tumour development has also been noted in a single
line of transgenic mice containing a mutant H-ras allele
under the control of a ζ-globin promoter. These animals
do not develop spontaneous tumours, but papillomas, car-
cinomas and fibrosarcomas arise in response to wounding
or TPA treatment [35]. H-ras expression has been shown
to occur only in response to such promotional stimuli in
these mice, and in situ hybridisation has shown that the
site of induced transgene expression is in the upper part of
the hair follicle [35]. The unique features of this mouse
line make comparisons with the present results, and with
chemically induced tumour development in normal mice,
very difficult.
A great deal of earlier evidence implicates the hair follicle
as a source of target cells for mouse skin tumour develop-
ment. Treatment, with tumour initiators and promoters, of
mice that had been subjected to epidermal abrasion,
resulting in removal of most of the interfollicular epider-
mis but leaving the follicles intact, still gave rise to sub-
stantial numbers of papillomas and carcinomas [36],
showing that some target cells must exist within the folli-
cles. More recently, Lavker and colleagues showed that
the bulge region of the hair follicle is the most likely loca-
tion of the epidermal stem cells [9], and that stimulation
of hair follicle growth before chemical initiation can
increase the number of papillomas which develop [11].
Additional evidence that target cells exist within hair folli-
cles came from analysis of tumour development in trans-
genic animals expressing ornithine decarboxylase under
the control of keratin 6 or keratin 5 promoters [37]. Malig-
nant progression frequency was not assessed in any of
these studies, however, and no conclusions could be
reached as to the differential locations of cells capable of
giving rise to either benign papillomas or carcinomas. Evi-
dence also exists for the presence within the epidermal
basal cell compartment of both a putative stem cell popu-
lation [6,7], and of target cells for tumour development
[38]. It has now been shown by specific targeting of the
initiating ras gene to the interfollicular cells [20,22] or to
the follicular compartment (this report) that target cells
can exist in both locations, but that those within the hair
follicle region are much more likely to form premalignant
tumours which progress to carcinomas.
Conclusions
Expression of mutant H-ras in the hair follicle of the skin
produces epithelial tumours with a high malignant capac-
ity. This contrasts markedly with the effects seen in previ-
ous studies of targeted H-ras expression in the
interfollicular epidermis, in which malignant conversion is
rarely observed. Tumour promoters appear to be more
important for the continued outgrowth of cells from the
interfollicular population that express mutant ras genes,
but these are less likely to become malignant. We con-
clude that, within the skin, there is a continuum of cell
populations capable of being initiated by mutation and of
giving rise to tumours, and that the nature and location of
the initiated cell determines the malignant capacity of the
resultant tumour.
Materials and methods
Generation of the K5ras gene construct 
A 1.3 kb Hind III–NruI fragment of the bovine keratin 5 promoter (K5)
was isolated from plasmid pKIII-5′ (provided by J. Jorcano) and placed
into the plasmid pIC20R. Subsequently, a 0.85 kb Bgl II–BamHI frag-
ment from pRSVβglobin [39], containing the SV40 small t intron and
polyadenylation signal (SV40poly(A)), was inserted into the Bgl II site.
Finally, a human H-ras cDNA fragment, containing a Val12 mutation,
was isolated as an EcoRI fragment from plasmid pEXV-KT (a gift from C.
Marshall) and cloned into the XhoI site of the K5–SV40poly(A) cassette.
Generation and identification of transgenic mice
The 3.1 kb K5ras construct was excised with BamHI and ClaI, purified,
and microinjected into the pronuclei of B6CBF2 hybrid fertilised
embryos, using established techniques [40]. Genomic DNA was
obtained from mice by tail-tip biopsy [41] and transgenic animals were
identified by PCR analysis. A 258 bp fragment of the H-ras transgene
was amplified using primers 5′-GATGGGGAGACGTGCCTGTTG
(bases 139–159) and 3′-GTCCTGAGCCTGCCGAGATTC (bases
396–376). A 386 bp fragment of the thyroid stimulating hormone β
chain was co-amplified as an internal control for the efficiency of the
amplification reaction [42]. The amplification conditions used were 35
cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 30 s. Transgene
copy number was determined by Southern blotting of KpnI-digested
DNA and hybridisation with the H-ras cDNA probe.
Histology
Tissues for histological examination were fixed in 4% phosphate-
buffered formalin overnight, dehydrated and embedded in paraffin by
standard methods. Sections (6 µm) were stained with haematoxylin
and eosin. Photomicrography was performed on an Olympus BX2
microscope using Ektachrome film (Kodak).
Immunoprecipitation and western blotting
Standard procedures were followed. Briefly, tumour samples were pul-
verised after snap-freezing in liquid nitrogen and dissolved in lysis
buffer containing Triton X-100 (Sigma). Samples were precleared
using anti-rat IgG Protein-A–Sepharose, followed by immunoprecipita-
tion using the anti-H-Ras monoclonal antibody YA6-172 [43] and anti-
rat IgG Protein-A–Sepharose. Resin pellets were washed in RIPA
buffer, and the samples resuspended in Laemmli buffer, prior to being
run on 12.5% SDS–polyacrylamide gels and electroblotted onto nitro-
cellulose (Schleicher & Schuell). Immunoblotting was carried out using
mouse monoclonal pan-Ras antibody Ras11 (Oncogene Science), and
binding visualised using horseradish-peroxidase-conjugated secondary
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antibody with ECL (Amersham) chemiluminescence detection and
autoradiography.
In situ hybridisation
Tumour samples were fixed overnight in fresh 4% paraformaldehyde at
4°C, dehydrated and embedded in paraffin wax. Sections (6 µm) were
used for in situ hybridisation with 35S-labelled SV40 antisense or
sense riboprobes [44]. Autoradiographic exposures were for 10 days.
Photomicrography was performed on an Olympus BX2 microscope
using Delta film (Ilford).
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